04:13 AM EST, 01/12/2026 (MT Newswires) -- Sanofi ( SNY ) said Monday the European Commission has approved its drug, Teizeild, to delay the onset of stage 3 type 1 diabetes in patients aged eight and older with stage 2 type 1 diabetes.

The company said the decision follows a recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use to approve the drug.

The drugmaker said the approval is based on a phase 2 study that showed that Teizield delayed progression to stage 3 type 1 diabetes by a median of two years compared with placebo.